Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04911114
Other study ID # H20-02654
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 15, 2021
Est. completion date December 31, 2022

Study information

Verified date May 2021
Source University of British Columbia
Contact Kelly Mackenzie
Phone 2508972609
Email kelly.mackenzie@ubc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will explore the feasibility (suitability), efficacy (research-setting outcomes), and participant satisfaction of a virtually-supervised 12-week exercise and diet intervention for women with ovarian cancer. It will include exercise, behavior change strategies, and guidance around healthy eating. Participants will be instructed and supervised virtually in two exercise sessions weekly for 12 weeks by a professional trained to deliver the program. An additional 1 exercise session per week, completed independently, will be added from weeks 4-12 of the program. Finally participants will participate in two separate virtual group nutrition sessions. Assessments will occur at baseline, end-of-intervention, and 6 months post-baseline.


Description:

Purpose: To assess the feasibility, preliminary efficacy, and patient perspectives of a 12-week supervised, virtually-delivered exercise and healthy eating program for women living with and beyond ovarian cancer. Hypothesis: The investigators hypothesize that the program will be feasible and will demonstrate efficacy, and that patient perspectives will be overall positive and in support of the program. Justification: Women living with and beyond ovarian cancer exercise at levels below the general population, and are at an increased risk for falls. Exercise and healthy eating programming is not a part of routine care. This project has the potential to demonstrate a feasible and relatively low-cost option for offering such programming. Objectives: the objectives of this program are: 1) Primary Objective: To measure the feasibility of delivering the BE-BALANCED program from a virtual (i.e. live video) setting. Feasibility will be evaluated per individual item based on a priori targets; 2) Secondary Objective: To evaluate the preliminary efficacy of the BE-BALANCED program; 3) Tertiary Objective: To evaluate patient satisfaction (post-intervention only) Research Design: This study is a prospective single-arm feasibility study. Statistical Analysis: The primary aim is feasibility. This will be evaluated using descriptive statistics, focusing on the program recruitment, attendance, attrition, and fidelity. For secondary and tertiary/exploratory aims, a repeated measures ANOVA will be performed for each measure to evaluate the change in outcomes from baseline and end of intervention (12-weeks) and 3-month follow-up. In addition to the RM-ANOVA, an effect size for each measure will be calculated based on the same time-frame comparisons. SPSS will be used to process data.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date December 31, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender Female
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria: 1. 50-75 years of age (women tend to be older at time of diagnosis, with a median age in Canada of 62 years); 2. Completed primary chemotherapy treatment (oral maintenance therapy allowed); 3. Are within one year of completion of primary chemotherapy without known recurrence; 4. Have access to a smartphone, tablet, laptop, or desktop computer with a camera and microphone, and a reliable internet connection; 5. Speak English, to ensure safety in delivery of the physical activity intervention Exclusion Criteria: 1. Do not pass pre-exercise screening for safety and do not subsequently provide written medical clearance from their physician to participate; 2. Do not consent to adhere to safety requirements to participate in a virtual delivery program (i.e., be seen on video for duration of class); 3. Experienced a fall requiring medical attention in the prior 6 months as individuals may be a higher risk for fall in a virtual physical activity program setting and would be more appropriate for referral to falls clinic

Study Design


Intervention

Behavioral:
Be-Balanced
The BE-BALANCED program will run for 12-weeks, with participants attending group-based virtual supervised exercise sessions twice weekly. Participants will complete an individual in-person assessment at baseline and again at end of intervention to collect physical outcome measures and will complete questionnaires electronically using REDCap, (or mailed version). Follow-up assessments will be administered electronically to each participant using REDCap at 3-months after program completion (24 weeks post-baseline).

Locations

Country Name City State
Canada Clinical Exercise Physiology Lab Vancouver British Columbia

Sponsors (2)

Lead Sponsor Collaborator
University of British Columbia British Columbia Cancer Agency

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluate patient satisfaction Overall satisfaction; measured on scale 0-7 with higher score meaning higher satisfaction. Baseline to 12 weeks
Primary Accrual Assessed by meeting accrual targets (number recruited) Baseline (0 weeks)
Primary Intervention Adherence Assessed as number of supervised virtual sessions that a participant attended, out of a total of 24 group exercise sessions, and number of self-directed sessions completed, out of a total of 9 sessions. Baseline to 12 weeks
Primary Attrition Assessed as number of drop-outs during the 12-week program. Baseline to 12 weeks
Primary Fidelity of group belonging Group Belonging Scale (0-20; higher is better) Baseline to 12 weeks
Secondary Physical function: Gait speed Measured by the gait speed portion of The Short Physical Performance Battery. Measured in seconds. Change from baseline to 12 weeks (end of intervention)
Secondary Physical function: Functional mobility Measured by 8 foot timed up and go (Seniors Fitness Test). Measured by distance in seconds. Change from baseline to 12 weeks (end of intervention)
Secondary Physical function: Lower extremity strength and endurance Measured by 30-second chair stand (Seniors Fitness Test). Measured in repetitions completed. Change from baseline to 12 weeks (end of intervention)
Secondary Physical function: Upper extremity strength and endurance Measured by 30-second biceps curl (Seniors Fitness Test). Measured in repetitions completed. Change from baseline to 12 weeks (end of intervention)
Secondary Physical function: Balance Measured by Functional Reach Test. Measured in centimeters. Change from baseline to 12 weeks (end of intervention)
Secondary Cardiovascular Fitness Measured by the Six Minute Walk test. Measured in meters. Change from baseline to 12 weeks (end of intervention)
Secondary Height Measured using stadiometer. Measured in meters Change from baseline to 12 weeks (end of intervention)
Secondary Weight Measured using a scale. Measured in kilograms Change from baseline to 12 weeks (end of intervention)
Secondary Body mass index Aggregated measure of height and weight, reported in kilograms/meter^2 Change from baseline to 12 weeks (end of intervention)
Secondary Waist circumference Measured in centimeters Change from baseline to 12 weeks (end of intervention)
Secondary Hip circumference Measured in centimeters Change from baseline to 12 weeks (end of intervention)
Secondary Health-related quality of life: Physical Health Measured by 36-item Short Form Health Survey; Norm-based 0-100, higher score represents better health Change from baseline to 12 weeks (end of intervention)
Secondary Health-related quality of life: Mental Health Measured by 36-item Short Form Health Survey; Norm-based 0-100, higher score represents better health Change from baseline to 12 weeks (end of intervention)
Secondary Depression and anxiety Measured by Hospital Anxiety and Depression Scale; Score range 0-21, higher score is higher depression and anxiety. Change from baseline to 12 weeks (end of intervention)
Secondary Usual physical activity levels Measured by Modified Godin Leisure Time Physical Activity questionnaire; Scoring range 0 - no specified maximum. Scoring < 14 units "insufficiently Active" ; 14-23 is "moderately active" and >=24 is "active". Change from baseline to 12 weeks (end of intervention)
Secondary Falls Measured by standard falls calendar for the duration of the study as number of falls. Change from baseline to 12 weeks (end of intervention)
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2